XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Background, Basis of Presentation, Economic Dependency and Significant Accounting Policies: - Basis of Presentation thru Fair Value of Financial Instruments (Details)
12 Months Ended
Feb. 28, 2022
USD ($)
item
Feb. 28, 2021
USD ($)
shares
Feb. 29, 2020
USD ($)
shares
Percentage of outstanding stock owned by the President and Chairman of the Board 81.00%    
Number of antineoplaston drugs that have received FDA approval | item 0    
Economic Dependency      
Significant external revenue $ 0 $ 0  
Accumulated deficit 125,838,483 124,861,827  
Losses incurred $ 976,656 1,203,998  
Income Taxes      
Uncertain tax positions   $ 0 $ 0
Loss Per Common Share      
Warrants and stock options excluded from calculation of diluted loss per share (in shares) | shares   1,600,000 1,600,000
Fair Value of Financial Instruments      
Number of financial instruments held for trading purposes | item 0    
Minimum      
Economic Dependency      
Estimated useful lives 5 years    
Maximum      
Economic Dependency      
Estimated useful lives 10 years